The Harvard Drug Group is recalling 876 cartons of Nifedipine Extended-Release Tablets (30 mg), a medication used to treat high blood pressure and chest pain, because the tablets failed routine stability testing for dissolution. When a drug fails dissolution testing, it means the medication may not release into the body at the intended rate, which can lead to the drug being less effective or causing unexpected side effects. Approximately 504 cartons of the 50-count dose and 372 cartons of the 100-count dose are affected by this recall.
If the medication does not dissolve properly, the patient may not receive the correct dose of Nifedipine over the intended timeframe. This could lead to poorly controlled blood pressure or an increase in chest pain (angina) incidents.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.